摘要
目的分析神经胶质瘤中缓激肽B2受体表达水平与病理分级的相关关系,为缓激肽及其类似物的临床应用提供实验依据.方法采用神经胶质瘤患者术后标本,用H&E染色进行神经胶质瘤的病理诊断及分级,用免疫组化法和Western Blot法测定不同病理分级的神经胶质瘤中缓激肽B2受体的表达水平.结果H&E染色显示26例神经胶质瘤中Ⅰ级为9例,Ⅱ级为9例,Ⅲ级为8例,Ⅳ级为0例.胶质瘤边缘水肿带不表达缓激肽B2受体,B2受体位于胶质瘤细胞.Western Blot结果显示在三组不同病理分级的神经胶质瘤中,B2受体表达水平为Ⅰ级与Ⅱ级(39480.88±5119.96对51354.25±6168.77,n=8,t=2.447,P＜0.05),Ⅰ级与Ⅲ级(39480.88±5119.96对73032.13±8802.71,n=8,t=7.710,P＜0.001),Ⅱ级与Ⅲ级(51354.25±6168.77对73032.13±8802.71,n=8,t=5.704,P＜0.001);神经胶质瘤中缓激肽B2受体表达水平与其病理分级Ⅰ级～Ⅲ级呈显著正相关(r=0.895,P＜0.001),呈Ⅰ级＜Ⅱ级＜Ⅲ级状况.免疫组化法显示在三组不同病理分级的神经胶质瘤中,B2受体阳性区域面积占切片面积的百分比值为Ⅰ级与Ⅱ级(3.54%±1.51%对8.47%±3.45%,n=8,t=3.698,P＜0.01),Ⅰ级与Ⅲ级(3.54%±1.51%对15.94%±1.68%,n=8,t=15.562,P＜0.001),Ⅱ级与Ⅲ级(8.47%±3.45%对15.94%±1.68%,n=8,t=5.505,P＜0.001);神经胶质瘤中缓激肽B2受体阳性区域面积占切片面积的百分比值与其病理分级Ⅰ级～Ⅲ级呈显著正相关(r=0.878,P＜0.001),呈Ⅰ级＜Ⅱ级＜Ⅲ级状况.结论神经胶质瘤B2受体表达水平与其病理分级Ⅰ级～Ⅲ级呈显著正相关,提示利用缓激肽及其类似物开放血肿瘤屏障的疗效差异可能与B2受体表达水平有关.
Objective To analyze the correlation between the expressing level of bradykinin B 2 receptor and pathological grade of gliomas, and supply experimental basis for clinical application of bradykinin or its analog. Methods The clinicopathologic findings were diagnosed by reviewing all hematoxylin and eosin (H&E) stained tissue sections. To determine the expressing level of bradykinin B 2 receptor in glioma, immunohistochemistry and Western blot methods were used. Results Results of H&E staining: In 26 cases of glioma there were 9 cases of grade I, 9 cases of grade II, 8 cases of grade III, and 0 case of grade IV. Bradykinin B 2 receptor localized on tumor cells while the cells of edematous band at the edge of glioma did not express B 2 receptor. Results of Western blot: grade I and grade II (39480.88 ±5119.96 vs 51354.25 ±6168.77, n =8, t =2.447, P <0.05); grade I and grade III (39480.88±5119.96 vs 73032.13± 8802.71, n =8, t =7.710, P <0.001); grade II and grade III (51354.25±6168.77 vs 73032.13±8802.71, n =8, t =5.704, P <0.001). There was a positive correlation between the expressing level of bradykinin B 2 receptor and the the pathological grade of glioma ( r =0.895, P <0.001) as grade I<grade II<grade III. Results of immunohistochemistry: grade I and grade II (3.54% 1.51% vs 8.47%±3.45%, n =8, t =3.698, P <0.01); grade I and grade III (3.54%±1.51% vs 15.94%±1.68%, n =8, t =15.562, P <0.001); grade II and grade III (8.47%±3.45% vs 15.94%±1.68%, n =8, t =5.505, P <0.001). There was a positive correlation between the positive position area ratio of bradykinin B 2 receptor and the pathological grade of glioma ( r =0.878, P <0.001) as grade I<grade II<grade III. Conclusion There was a positive correlation between the expressing level of bradykinin B 2 receptor and the pathological grade of glioma. This may be the reason of the diverse cure effects of the increase of blood-tumor barrier permeability induced by bradykinin and its ana
出处
《神经科学通报》
CSCD
2005年第2期135-140,共6页
Neuroscience Bulletin
基金
This work was supported by the Natural Science Foundation of China No.30070268
No.30070768
Natural Science Foundation of Liaoning Province No.20022067
No.20022061
Start-up Foundation of Retumed Students Studied Aboard 2000 No.367.
